Half-year report · HY
3349.TEDINET S100XEJG
Period2025-06-01 → 2025-11-30
Filed2026-01-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥537.2bn | 2025-06-01 → 2025-11-30 | Cons. | Net sales |
| Revenue | ¥1.01T | 2024-06-01 → 2025-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥505.9bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Operating income | ¥20.7bn | 2025-06-01 → 2025-11-30 | Cons. | Operating income |
| Operating income | ¥20.3bn | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Ordinary income | ¥21.9bn | 2025-06-01 → 2025-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥43.2bn | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥21.8bn | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥21.7bn | 2025-06-01 → 2025-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥21.4bn | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥14.6bn | 2025-06-01 → 2025-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥31.0bn | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.4bn | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥14.6bn | 2025-06-01 → 2025-11-30 | Cons. | Profit loss |
| Net income | ¥14.4bn | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Total assets | ¥542.7bn | at 2025-11-30 | Cons. | Assets |
| Total assets | ¥524.8bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥486.6bn | at 2024-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥273.6bn | at 2025-11-30 | Cons. | Liabilities |
| Total liabilities | ¥267.3bn | at 2025-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥269.1bn | at 2025-11-30 | Cons. | Net assets |
| Net assets / equity | ¥257.5bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥243.5bn | at 2024-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥43.2bn | at 2025-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥57.0bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥43.2bn | at 2025-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥57.0bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥39.1bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥52.3bn | at 2024-05-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥22.1bn | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥52.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥15.1bn | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥29.0bn | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥55.4bn | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥22.5bn | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥7.0bn | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥7.7bn | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥5.7bn | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥184.83 | 2025-06-01 → 2025-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥390.86 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥182.05 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 49.6% | at 2025-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.1% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.0% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 428
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of treasury stock fin cf | Prior1InterimDuration | -1000000 | JPY |
| Purchase of treasury stock fin cf | InterimDuration | -0 | JPY |
| Repayments of finance lease obligations fin cf | Prior1InterimDuration | -1075000000 | JPY |
| Repayments of finance lease obligations fin cf | InterimDuration | -1225000000 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -2380000000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -2971000000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | -5748000000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | -6979000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | － | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | － | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | -13172000000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | -13797000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 52301000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 57038000000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 39129000000 | JPY |
| Cash and cash equivalents | InterimInstant | 43241000000 | JPY |
| Salaries and bonuses sga | Prior1InterimDuration | 39325000000 | JPY |
| Salaries and bonuses sga | InterimDuration | 43119000000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 142000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 155000000 | JPY |
| Rents sga | Prior1InterimDuration | 12156000000 | JPY |
| Rents sga | InterimDuration | 13104000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)福岡財務支局長 | |
| Filing date cover page | FilingDateInstant | 2026-01-14 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第44期中(自 2025年６月１日 至 2025年11月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社コスモス薬品 | |
| Company name in english cover page | FilingDateInstant | COSMOS Pharmaceutical Corporation | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 横山 英昭 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)福岡県福岡市博多区博多駅東二丁目10番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)092－433－0660（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役経営企画部長 柴田 太 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)福岡県福岡市博多区博多駅東二丁目10番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)092－433－0660（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経営企画部長 柴田 太 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E03446 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 33490 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社コスモス薬品 | |
| Filer name in english | FilingDateInstant | COSMOS Pharmaceutical Corporation | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |